Summary:
The intent of the FY25 Toxic Exposures Research Program (TERP) Clinical Trial Partnership Award (CTPA) is to support new or existing collaborative partnerships that will rapidly implement clinical trials with the potential to have a significant impact on the prevention, treatment or management

credit:

How's Your Community Doing?
Check Out it's
Community Vital Signs

of symptoms, diseases, or conditions associated with or resulting from military-related toxic exposures.

Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations.Distinctive Features:
To encourage applications that include meaningful and productive collaborations between investigators, the FY25 TERP CTPA requires partnership of the Initiating Principal Investigator (PI) with at least one, and up to two, other collaborating PIs for the completion of one overarching study.